Search This Blog

Sunday, December 5, 2010

Kindler quits

Talk about unexpected. The CEO and Chairman of the largest pharmaceutical company in the world, Pfizer, Jeff Kindler announced an immediate retirement.

I can certainly speculate endlessly about this, ranging from:

He quit because he feared the market effect of the potentially non-productive short-term pipeline.


The board let him go because within in 5yrs the stock went from a high of 23 to 17. A 26% decline. (The further one goes back, the uglier it gets.)

Having a lot of cash, and a very nice cash flow, can fog up an investor's judgment quite a bit. Pfizer bought Wyeth to make up for its potential cash-flow issue due to patent expiration. Instead of innovating itself out of their hole, they took a strategy out of their predictive play book. Acquire, and reduce. (Anyone that has studied these types of M&As can attest that 'acquiring and reducing expenses' is not an efficient strategy.)

The problem with certain acquisitions is that they do not work when both companies are projected to lose a substantial amount of revenue w/in the next 1-2yrs. Synergies will simply not cover high revenue losses, especially biotech/pharma synergies. (This is simply fact, and the nature of the specific-product-dependent driven pharma business.)

There is no question Pfizer is an efficiently run company, and I am sure Kindler facilitated in creating the efficiency, but it has been lacking the proper strategic vision. Unfortunately, under Kindler's leadership, the company has talked a big game, but its actions were not innovative and seriously questionable.

No comments:

Post a Comment